drugset / Trial / NCT06015659
ZN-c3 + Gemcitabine in Pancreatic Cancer
Phase 2
Active not recruiting
12 enrolled
Brandon Huffman, MD
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · collabLustgarten Foundation · collabStand Up To Cancer · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: * ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) * Gemcitabine (a nucleoside metabolic inhibitor)
Timeline
- Start
- 2023-11-16
- Primary completion
- 2025-08-06
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azenosertib | Small molecule | — | Oral |
| Subject | Gemcitabine | Small molecule | — | Intravenous |